| Dr Michael Paul Stany, MD | |
|
300 20th Ave N, Suite 602, Nashville, TN 37203-2131 | |
| (615) 284-4646 | |
| (615) 284-4675 |
| Full Name | Dr Michael Paul Stany |
|---|---|
| Gender | Male |
| Speciality | Gynecological Oncology |
| Experience | 22 Years |
| Location | 300 20th Ave N, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740266832 | NPI | - | NPPES |
| 770706389 | Other | MD | DOD/TRICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0201X | Obstetrics & Gynecology - Gynecologic Oncology | MD61971 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Thomas West Hospital | Nashville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Thomas Medical Partners | 1557269354 | 519 |
News Archive
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Since the start of the COVID-19 pandemic, the causative virus, SARS-CoV-2, has undergone several mutations.
Viruses attack specific host cells, which can cause chaos in the body. The novel coronavirus, now called severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 for short, infects respiratory epithelial cells in the lining of the lung, causing difficulty of breathing. The usual cause of death of those who contract the virus is pneumonia and acute respiratory distress syndrome (ARDS). Now, a new study has found that SARS-CoV-2 specifically attack certain progenitor cells called bronchial transient secretory cells in the lungs.
The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
› Verified 4 days ago
| Entity Name | Saint Thomas Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437194669 PECOS PAC ID: 1557269354 Enrollment ID: O20031230000470 |
News Archive
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Since the start of the COVID-19 pandemic, the causative virus, SARS-CoV-2, has undergone several mutations.
Viruses attack specific host cells, which can cause chaos in the body. The novel coronavirus, now called severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 for short, infects respiratory epithelial cells in the lining of the lung, causing difficulty of breathing. The usual cause of death of those who contract the virus is pneumonia and acute respiratory distress syndrome (ARDS). Now, a new study has found that SARS-CoV-2 specifically attack certain progenitor cells called bronchial transient secretory cells in the lungs.
The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Paul Stany, MD 300 20th Ave N, Suite 602, Nashville, TN 37203-2131 Ph: (615) 284-4646 | Dr Michael Paul Stany, MD 300 20th Ave N, Suite 602, Nashville, TN 37203-2131 Ph: (615) 284-4646 |
News Archive
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Since the start of the COVID-19 pandemic, the causative virus, SARS-CoV-2, has undergone several mutations.
Viruses attack specific host cells, which can cause chaos in the body. The novel coronavirus, now called severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 for short, infects respiratory epithelial cells in the lining of the lung, causing difficulty of breathing. The usual cause of death of those who contract the virus is pneumonia and acute respiratory distress syndrome (ARDS). Now, a new study has found that SARS-CoV-2 specifically attack certain progenitor cells called bronchial transient secretory cells in the lungs.
The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.
› Verified 4 days ago
Barbara H Nylander, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 345 23rd Ave N, Suite 209, Nashville, TN 37203 Phone: 615-329-9082 Fax: 615-329-2423 | |
Dr. Vernita Ann Tucker, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-5524 Fax: 615-327-5541 | |
Alexandra Jordan Douglas Phelps, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-936-2000 | |
Douglas H Brown, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 300 20th Ave N Ste 302, Nashville, TN 37203 Phone: 615-284-2988 Fax: 615-284-2995 | |
Barry S Grimm, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Shannon Marie Madison, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2011 Murphy Ave Ste 601, Nashville, TN 37203 Phone: 615-329-6622 Fax: 615-329-6785 | |
Mckenzie Diane Canon, APRN Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-5000 |